ITUS (ITUS) Earns Daily Media Impact Score of 0.21
News headlines about ITUS (NASDAQ:ITUS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ITUS earned a news impact score of 0.21 on Accern’s scale. Accern also assigned media coverage about the business services provider an impact score of 47.126963856316 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
- ValuEngine Lowers ITUS (ITUS) to Sell (americanbankingnews.com)
- ITUS Corp Expected to Earn FY2017 Earnings of ($0.58) Per Share (ITUS) (americanbankingnews.com)
- ITUS Will Present Data on Early Cancer Detection Technology at ASCO-SITC Symposium (finance.yahoo.com)
- SeeThruEquity Initiates Coverage on ITUS Corporation (NASDAQ: ITUS) with a Price Target of $5.00 (finance.yahoo.com)
- ITUS Corporation (ITUS): Should The Recent EPS Drop Worry You? (finance.yahoo.com)
Separately, ValuEngine downgraded shares of ITUS from a “hold” rating to a “sell” rating in a research note on Thursday.
TRADEMARK VIOLATION WARNING: “ITUS (ITUS) Earns Daily Media Impact Score of 0.21” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/itus-itus-earns-daily-media-impact-score-of-0-21/1756166.html.
ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream.
Receive News & Ratings for ITUS Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS Corp and related companies with MarketBeat.com's FREE daily email newsletter.